



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Chun-Nan Yeh
yehchunnan@gmail.com

†These authors have contributed
equally to this work

SPECIALTY SECTION
This article was submitted to
Gastrointestinal Cancers: Gastric and
Esophageal Cancers,
a section of the journal
Frontiers in Oncology

RECEIVED 01 September 2022
ACCEPTED 06 September 2022
PUBLISHED 13 October 2022

CITATION
Lin L-C, Huang W-K, Yen C-C,
Yang C-Y, Sung M-T, Wong NSM,
Chua DTT, Lee SWM, Chen J-S and
Yeh C-N (2022) Corrigendum:
Compassionate use of ripretinib for
patients with metastatic
gastrointestinal stromal tumors:
Taiwan and Hong Kong experience.
Front. Oncol. 12:1028118.
doi: 10.3389/fonc.2022.1028118

COPYRIGHT
© 2022 Lin, Huang, Yen, Yang, Sung,
Wong, Chua, Lee, Chen and Yeh. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience

Li-Ching Lin^{1†}, Wen-Kuan Huang^{2†}, Chueh-Chuan Yen^{3,4},
Ching-Yao Yang⁵, Meng-Ta Sung⁶, Natalie S. M. Wong⁷,
Daniel T. T. Chua⁸, Sarah W. M. Lee⁹, Jen-Shi Chen²
and Chun-Nan Yeh^{1*}

¹Department of Surgery and GIST Team, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan, ²Division of Hematology-Oncology, Department of Internal Medicine and GIST Team, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan, ³Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan, ⁵Department of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan, ⁶Department of Oncology, Mennonite Christian Hospital, Haulien, Taiwan, ⁷Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong SAR, China, ⁸Department of Medicine, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong SAR, China, ⁹Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong SAR, China

KEYWORDS

ripertinib, GIST, compassionate use, advanced, metastatic

A Corrigendum on

Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience

by Lin L-C, Huang W-K, Yen C-C, Yang C-Y, Sung M-T, Wong NSM, Chua DTT, Lee SWM, Chen J-S and Yeh C-N (2022) *Front. Oncol.* 12:883399. doi: 10.3389/fonc.2022.883399

In the published article, there was an error in affiliations 3 and 4. Instead of “3. Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Taipei, Taiwan, 4 Department of Oncology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan”, it should be “3. Division of Clinical Research, Department of Medical Research and Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, 4. National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan”.

In the published article, an author name was incorrectly written as “Sean M.N. Wong”. The correct spelling is “Natalie S.M. Wong”.

In the published article, there was an error in the Funding statement. An acknowledgement was missed. The correct Funding statement appears below.

Funding

This work was supported in part by the Chang Gung Memorial Hospital CMRPG3J0971~3 CORPG3J0251~3. We thank to Zai Lab (Taiwan) Limited for the educational grant to Taiwan Society of Molecular Medicine. The funder Zai Lab (Taiwan) was not involved in the study design, collection,

analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.